Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 Indications 2 Adverse effects 3 Chemistry 4 Availability 5 References

Bromopride

●العربية ●Italiano ●Português ●Română ●Русский ●Српски / srpski ●Srpskohrvatski / српскохрватски Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version In other projects ●Wikimedia Commons Appearance From Wikipedia, the free encyclopedia

Bromopride
Clinical data


AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, IM, IV
ATC code	A03FA04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	50 to 75% (oral) 78% (intramuscular)
Protein binding	40%
Metabolism	Hepatic
Elimination half-life	4 to 5 hours
Excretion	Renal, 10 to 14% unchanged
Identifiers
IUPAC name 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
CAS Number	4093-35-0^N
PubChem CID	2446
DrugBank	DB09018^N
ChemSpider	2352^Y
UNII	75473V2YZK
KEGG	D07101^Y
ChEMBL	ChEMBL399510^Y
CompTox Dashboard (EPA)	DTXSID0045383
ECHA InfoCard	100.021.675
Chemical and physical data
Formula	C₁₄H₂₂BrN₃O₂
Molar mass	344.253 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Brc1cc(c(OC)cc1N)C(=O)NCCN(CC)CC
InChI InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)^Y Key:GIYAQDDTCWHPPL-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.^[1]

Indications[edit]

Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.

Adverse effects[edit]

Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as with metoclopramide, may increase prolactin levels.^[2]

Chemistry[edit]

Bromopride is a substituted benzamide, closely related to metoclopramide.^[3] It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.

Availability[edit]

Bromopride is not available in the United States or the United Kingdom. It is marketed in BrazilbySanofi-Synthélabo under the trade name Digesan, by LIBBS under the name Plamet, and as a generic drug.

References[edit]

^ Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy". J Bras Ginecol (in Portuguese). 91 (4): 283–5.

^ "Bula do Profissional de Saúde: Bromoprida". Bulário Eletrônico da Anvisa (in Portuguese). Brazilian National Health Surveillance Agency. April 11, 2006. Archived from the original on September 28, 2007. Retrieved 2007-07-23.

^ Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos. 7 (3): 215–22. doi:10.1002/bdd.2510070302. PMID 3730521.